Comparative TERF2 Gene Activity and TRF2 Protein-Pathway Profiling in Human Liver and Gastric Tumors: A Tissue-Based Diagnostic Biomarker Study of Tumor Development

TERF2 TRF2 liver tumors gastric tumors biomarker telomere biology

Authors

September 30, 2025

Downloads

Cells that are cancerous need to keep their chromosome ends intact while surviving replication stress, DNA damage response remodeling, and continued proliferation. Telomere protection is becoming more and more recognized as an important factor in tumor development. Protecting the ends of chromosomes is what TERF2 does. It creates the shelterin protein TRF2, which may change gene-regulatory and microenvironmental processes outside of telomeres. Unfortunately, there aren't many direct comparisons between human tissues that include TERF2 gene activity, TRF2 protein expression, pathway behavior, and diagnostic modeling in liver and stomach tumors. Using protocol-defined criteria, this observational comparative molecular pathology study looked at 100 original human tumor samples, 50 of which were liver tumors and 50 of which were stomach tumors the study was conducted in March 2025 and concluded in June 2025. Cases that were recurring, metastatic, previously treated, poor-quality, or linked with a chronic disease were not included. DNA damage response and proliferation pathway behavior was studied using γ-H2AX, p-ATM, p53, and Ki-67 marker profiling. TERF2 mRNA levels were measured by RT-qPCR, and nuclear TRF2 protein levels were quantified by immunohistochemistry. There was no significant difference between the two groups in terms of nuclear TRF2 H-scores, but there was a difference between stomach and liver tumors in terms of TERF2 relative expression (median 2−ΔCt, 0.120 vs. 0.084; p =.0037). TRF2 H-score and TERF2 expression were linked (Spearman ρ =.588; p <.001), and aggressive tumors had higher TRF2 H-score and pathway score. According to the results of a combination TERF2/TRF2/pathway model, there was good internal diagnostic differentiation for aggressive tumor-development trait (AUC = 0.916; bootstrap-corrected AUC = 0.907). Additionally, these results show that TERF2/TRF2 pathway profiling is a promising tissue-based diagnostic indicator of tumor-development biology that needs to be confirmed by other scientists before it can be used in patients.

Similar Articles

1 2 3 4 5 6 > >> 

You may also start an advanced similarity search for this article.